


**Westminster Health Forum policy conference:
Next steps for cancer research and genomics in England**

Timing: Morning, Thursday, 7th January 2027

*****Taking place online*****



**WESTMINSTER
HEALTH FORUM**

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**
Dr Scott Arthur MP
- 9.05 **Assessing latest developments in cancer policy and research - implementation, capacity and considerations for the next phase**
Senior commentator
Questions and comments from the floor
- 9.25 **Patient priorities for cancer research, genomic testing and personalised care**
Richard Stephens, Chair, Cancer Research Advocates Forum
- 9.35 **Advancing research and innovation in prevention, early detection and multi-cancer screening**
evaluating emerging approaches to earlier diagnosis | development of multi-cancer early detection tests | lessons from the NHS-Galleri Trial and implications of trial outcomes | clinical utility, cost-effectiveness and evidence thresholds for adoption | integrating blood, breath and urine diagnostics | strengthening liquid biopsy capability | sequencing national early detection priorities | coordination across NIHR, NHS Cancer Programme and OLS | AI-supported diagnostic interpretation | integrating novel diagnostics into NHS screening and referral pathways | strengthening diagnostic capacity and pathology services | impact on primary care and alignment with neighbourhood-based care | addressing variation in access and uptake across communities | overdiagnosis, false reassurance and informed consent
Prof Alastair Greystoke, Professor of Precision Oncology; and Honorary Consultant in Medical Oncology, Newcastle University
Senior representative, NHS
Senior representative, diagnostics
Senior representative, workforce
Senior representative, screening
- 10.00 Questions and comments from the floor
- 10.25 **Next steps for genomics across the cancer pathway - consistency, access and clinical application**
Dr Nirupa Murugaesu, Cancer Lead, Genomics England
Questions and comments from the floor
- 10.50 **Chair's closing remarks**
Dr Scott Arthur MP
- 10.55 Break
- 11.05 **Chair's opening remarks**
Senior Parliamentarian
- 11.10 **Implementation of genomics in cancer care - NHS Genomic Medicine Service delivery, routine testing and personalised insights**
Professor Dame Sue Hill, Chief Scientific Officer, England, NHS England
Questions and comments from the floor
- 11.35 **Data and digital infrastructure for cancer research and personalised care - access, governance and public trust**
Senior representative, data
- 11.45 **Clinical trials, rare cancer research and access to new treatment**
implementation of the new UK clinical trials regulations | Cancer Trials Accelerator Programme implementation and national standards | trial-ready infrastructure, high-throughput testing sites and specialist workforce requirements | NHS research capacity and protecting non-commercial and academic studies | streamlining regulatory processes | decentralised and community-based trial delivery | addressing barriers to participation for underserved groups | increasing participation in trials for rare cancers, children and young people | implementation of the Rare Cancers Act 2026 and arrangements for identifying and contacting potential trial participants | personalised mRNA vaccines, cell and gene therapies | evidence generation for molecular and genomic therapies | adoption pathways and system readiness for innovative treatments | interaction between MHRA authorisation, NICE appraisal and NHS commissioning | national leadership and priority-setting for rare cancers | orphan drug regulation and the route to reimbursement
Cameron Miller, Vice Chair, Less Survivable Cancers Taskforce; and Director, External Affairs and Strategy, The Brain Tumour Charity
Senior representative, NHS
Senior representative, industry
Senior representative, ethics
Senior representative, patients
- 12.10 Questions and comments from the floor
- 12.35 **Next steps for regulatory frameworks for personalised therapies and pathways to innovative treatment adoption**
Julian Beach, Interim Executive Director, Healthcare Quality and Access, Medicines and Healthcare products Regulatory Agency
Questions and comments from the floor
- 13.00 **Chair's and Westminster Health Forum closing remarks**
Senior Parliamentarian
Jessica Lear, Westminster Health Forum